Ajanta Pharma Results Earnings Call for Q2FY24
Conference Call with Ajanta Pharma Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.31-10-2023
31-10-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Ajanta Pharma Ltd.
Pharmaceuticals company Ajanta Pharma announced Q2FY24 & H1FY24 results: Q2FY24: Revenue from operations at Rs 1,028 crore against Rs 938 crore; up 10%. EBITDA at Rs 291 crore against Rs 196 crore; up 48%; EBITDA at 28%. Profit after tax at Rs 195 crore against Rs 157 crore; up 25%; PAT at 19%. Q2FY24, R&D; expenses were Rs 50 crore, (Rs 59 crore), 5% of revenue H1FY24: Revenue from operations at Rs 2,049 crore against Rs 1,889 crore; up 8%. EBITDA at Rs 572 crore against Rs 418 crore; up 37%; EBITDA at 28%. Profit after tax at Rs 403 crore against Rs 331 crore; up 22%; PAT at 20%. H1FY24, R&D; expenses were Rs 105 crore, (Rs 113 crore), 5% of revenue. Result PDF31-10-2023
AJANTA PHARMA LTD. - 532331 - Results For Second Quarter And Half Year Ended 30Th September 2023
Results for the Second Quarter and Half Year Ended 30th September 2023.31-10-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
PFA herewith results for H1 FY 202431-10-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 31st October 2023, post Board meeting.19-10-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Approving Financial Results
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 ,inter alia, to consider and approve Unaudited Consolidated and Standalone Financial Results for the second quarter and half year ended 30.09.202319-10-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2023.09-10-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 30, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust30-09-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 29, 2023 for Ravi Agrawal, trustee Ravi Agrawal Trust29-09-2023
AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (PIT) Regulations, 2015 as amended from time to time, trading window shall be closed from the close of business hours of Saturday, 30th September 2023 till 48 hours after the declaration of the financial results of the Company.28-09-2023